Coronary microvascular dysfunction (CMD) is a major mechanism of myocardial ischemia and adverse cardiovascular outcomes in patients with angina or dyspnea, both in the absence and in the presence of obstructive coronary artery disease. Because the coronary microcirculation cannot be visualized directly with routine an...
Panagiotis Theofilis, A. Sakalidis, Kyriakos Dimitriadis et al.· Medicina· 0 citations
Background/Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD), the hepatic manifestation of cardiometabolic dysfunction, is closely linked to atherosclerosis, heart failure, and adverse cardiovascular outcomes. This review summarizes current evidence on the biological basis of the MASLD–heart...
Evangelos Oikonomou, N. Machairas, Panagiotis Theofilis et al.· Pharmaceuticals· 0 citations
INTRODUCTION
Transcatheter aortic valve implantation (TAVI) has become an established treatment for severe aortic stenosis across an expanding risk spectrum. As indications extend to younger and lower-risk patients, post-treatment complications with implications for survival, quality of life, and valve durability requi...
Panagiotis Theofilis, P. Vlachakis, George Koutsopoulos et al.· Expert Review of Cardiovascu...· 0 citations
BACKGROUND
Congenital complete atrioventricular block (CCAVB) requires pacing from early life, yet the long-term burden of pacing-induced cardiomyopathy (PICM), mortality, and device-related complications has not been quantitatively synthesized.
OBJECTIVE
To determine the incidence of PICM, mortality, and device-rela...
P. Vlachakis, Panagiotis Theofilis, Maria Drakopoulou et al.· Heart Rhythm· 0 citations
Why injectable lipid-lowering therapies in advanced CKD merits serious consideration is highlighted - not only for their potent and durable lipid-lowering effects, but also for their ability to target other paths that contribute to the excess CV risk not captured by LDL alone.
A. Damianaki, E. Stambolliu, P. Iliakis et al.· Cardiovascular Drugs and The...· 0 citations
A better understanding of CKD-CM pathogenesis is likely to enable early intervention and prevention, with successful outcomes measured by reduced progression to severe cardiomyopathy and lower cardiovascular mortality in CKD.
Konstantinos Grigoriou, Vasileios Lamprou, Anastasios Chatzichidiroglou et al.· British journal of hospital...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
